TEANECK, N.J., March 12, 2012 /PRNewswire/-- Herborium Group, Inc. (HBRM.PK), www.herborium.com, is pleased to announce that the Phase 1 of due diligence for the sale of up to 100% interest to China Health Resources Inc (OTCBB:CHRI.OB -News) has been completed. "We are very pleased with a timely progress of a due diligence and the completion of the First Phase of the process that is the exchange of the confidential information and documentation," stated Dr. Agnes P. Olszewski CEO of Herborium Group.

"As we have stated in our Press Release of 02/24/2012 regarding a signed Letter of Intent with China Health Resource Inc., both parties are highly motivated to complete the process successfully and in a timely fashion while guided by their  fiduciary responsibilities.  Both parties are truly excited about the opportunity and remain most optimistic of a smooth transaction and final agreement," concluded Dr. Olszewski.

About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals.  The Company uses clinical validation to establish and maintain a differential advantage. The company sales its products in the US and Europe. For more information, please visit www.herborium.com and www.acnease.com. 

One of our most important responsibilities is to communicate with shareholders in an open and direct manner.  Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends."  We cannot promise future returns.  Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events.  The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

For more information please inquire: Investorsrelations@herborium.com